TCTMD vs BifurcAID
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
TCTMD
Access cardiovascular news, journal summaries, conference coverage, and case studies. View slide presentations and videos in a mobile-friendly format.
- Daily news articles
- Journal summaries
- Conference coverage
- Case study library
- Slide presentation library
- Video library
Read full descriptionHide full description
The TCTMD app provides TCTMD subscribers with mobile access to content found on the TCTMD web site. Content includes: - Daily news articles, including journal summaries as well as cardiovascular conference coverage. - The case study, slide presentation, & video libraries are also available in a mobile friendly format with easily viewed reports, slides & videos respectively.
BifurcAID
This educational tool provides step-by-step visual guidance for performing coronary bifurcation interventions. It is designed to help medical professionals learn and practice complex procedures.
- Step-by-step illustrations
- Coronary bifurcation intervention guidance
- Educational tool for medical professionals
- Visual learning aid
Read full descriptionHide full description
BifurcAID is an educational tool with step by step illustrations of how to perform coronary bifurcation interventions.
Screenshots
Verdict
The clearest difference is rating: BifurcAID at 5.0 against TCTMD's 4.0. BifurcAID also leads on ads (none vs shown) and ratings volume (16 vs 1). On price, update cadence, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
BifurcAID holds the better App Store score, 5.0 against 4.0. That said, the two scores are not equally well evidenced: BifurcAID has 16 ratings behind it against 1, so its average is the more settled of the two. Written reviews point the same way: 86% of TCTMD's written reviews are positive against 100% of BifurcAID's.
Both ship on a similar rhythm, roughly every 3 months. The most recent releases landed on July 6, 2026 and June 4, 2026 respectively.
| Parameter | TCTMD | BifurcAID |
|---|---|---|
| Price | Free | Free |
| Rating | 4.0 (1 ratings) | 5.0 (16 ratings) — better |
| Positive reviews | 85.7% of reviews | 100.0% of reviews — better |
| Number of ratings | 1 | 16 — better |
| Update frequency | Every 3 months | Every 3 months |
| Ads | Yes | No — better |
| In-app purchases | No | No |
| Monetization | Ad-supported | Free — better |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 15.1 | 13.0 — better |
| Further details — not scored | ||
| Size | 30 MB | 55 MB |
| Age rating | 12+ | 17+ |
| Developer | Cardiovascular Research Foundation | Icahn School of Medicine at Mount Sinai |
Customer experience
TCTMD
BifurcAID
In-app purchases
TCTMD
No in-app purchases
BifurcAID
No in-app purchases
